LB Pharma shareholders elect three Class I directors, ratify auditor at annual meeting

LB PHARMACEUTICALS INC

Class I directors elected: Robert A. Lenz (20,059,577 for), Rebecca Luse (18,530,680), Ran Nussbaum (18,748,511).
Broker non-votes of 3,216,636 on each director election.
Ratification of BDO USA as auditor for FY 2026: 23,275,974 for, 5,490 against, 2,753 abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LB PHARMACEUTICALS INC shareholders approved Ratification of the appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LB PHARMACEUTICALS INC shareholders approved Election of Class I Directors to serve three-year terms until 2029 at the 2026-06-03 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-03

Exact text from the filing

The Company’s stockholders elected the three persons listed below as Class I directors, each to serve a three-year term until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal.

View on SEC.gov

1671 shareholder votes filed in the last 30 days. Browse all shareholder votes →

LB PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-263724

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.